Latest Content

Jade Coats, OD, FAAO, stated that providing pre- and post-op patient care can provide an opportunity to support ophthalmologists.

Through at home delivery, and in-office dispense in permitted states, Orasis Pharmaceuticals and BlinkRx aim to improve accessibility of Qlosi eye drops for presbyopia treatment.

Protecting eye health today requires more than regular eye exams and good lighting

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the US.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

The FDA confirmed phase 1 and nonclinical data support pediatric phase 2 development of IVMED-85, a non-atropine daily eye drop for myopia progression.

Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, and faster workflow.

Frantz EyeCare reported 98% of Light Adjustable Lens patients within ±0.50 D of target but omitted cohort, follow-up, and safety details.

i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.

Jessica Steen, OD, FAAO, DipABO, stated that each ADC can have distinct ophthalmic monitoring needs and management protocols.

Lab-grown retinal endothelial cells from iPSCs rebuild mouse retinal vessels and power blood-retina barrier chips, accelerating diabetic retinopathy research and therapy discovery.

A disconnect between the signs and symptoms of OSD can easily lead to misdiagnosis or undertreatment if clinicians rely solely on a slit lamp observation.

University of Waterloo unveils chairside 3D-printed contacts, delivering custom-fit lenses in 20 minutes—potentially cutting weeks of trial fittings for irregular corneas.